Here are the 10-K annual reports from Becton, Dickinson and Co. (BDX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDX filings page.
Becton, Dickinson and Company (BDX) is a global medical technology company that develops and sells medical supplies, devices, lab equipment and diagnostic products used across hospitals, labs, pharma and home care. As of September 30, 2025, it operated three segments—BD Medical, BD Life Sciences and BD Interventional—covering infusion and medication systems, diagnostic platforms, cell analysis tools and a wide range of surgical, vascular and urology products.
BD completed the $3.914 billion acquisition of Edwards Lifesciences’ Critical Care product group in 2024, now BD Advanced Patient Monitoring. In July 2025, BD agreed to combine its Biosciences and Diagnostic Solutions businesses with Waters Corporation via a Reverse Morris Trust, with BD shareholders expected to own about 39.2% of the combined company and BD expecting an approximately $4 billion cash distribution, while Waters is expected to assume about $4 billion of incremental debt, subject to approvals and other conditions.
BD has also reshaped its portfolio through the 2023 sale of its Surgical Instrumentation platform and the 2022 spin-off of Embecta, its former Diabetes Care business. The company operates globally with manufacturing and R&D centers across the U.S., Europe and Asia and faces detailed regulatory oversight, including an FDA consent decree related to infusion pumps and a Warning Letter tied to Pyxis dispensing systems, for which it is implementing corrective actions.